Roche Holdings is seeking a replacement internally for its outgoing pharma chief Bill Anderson amid increased pressure to refresh its portfolio of medicines, Bloomberg’s Naomi Kresge reports, citing comments made by chairman Christoph Franz. "There are always risks when someone comes as a chief who isn’t familiar with the culture of the company," said Franz, who is departing the chairman’s position in March. "The risk is much less great when it’s someone who’s already been in the company for some time." Reference Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RHHBY:
- Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
- Sonnet BioTherapeutics, Roche collaborate for SON-1010 with atezolizumab
- Genentech announces FDA acceptance of, grants priority review for glofitamab BLA
- FDA grants priority review to Roche’s bispecific antibody glofitamab for people with relapsed or refractory large B-cell lymphoma
- Nimble Therapeutics announces expansion of partnership with Genentech